Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

Vectura board backs Philip Morris takeover bid over The Carlyle Group offer

The board plans to unanimously recommend the $1.5bn bid from Philip Morris to shareholders

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

Impetus Digital

Biotech Innovation in the Time of COVID-19

Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

Impetus Digital

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone.Founded in...

Lucid Group Communications Limited

- PMLiVE

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Development and commercialisation deal could be worth up to $1.08bn

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment

Onyx Health

Newcells Biotech secures over £5m for 3D tissue models

Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models

Onyx Health

- PMLiVE

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial

- PMLiVE

Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

Three-year collaboration agreement will seek to develop a range of therapeutic candidates

- PMLiVE

New medical communications agency BOLDSCIENCE launches

The new global agency boldly sets out its plans to become a major player in med comms

BOLDSCIENCE

Virtual Reality in Medicine and Clinical Research

In the latest episode of Impetus Digital's Fireside Chat, I sit down with Ville Leppälä, Vertical Lead, Research and Medical, at Varjo. We discuss the potential applications of virtual reality, augmented...

Impetus Digital

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links